Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H56 + IC31
- Development stage
- Unknown
- Lead developer
- Statens Serum Institut
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
H56 + IC31 (AERAS-456) is a recombinant protein subunit vaccine candidate developed by the Statens Serum Institute (SSI) and Aeras for the prevention and treatment of tuberculosis (TB). The vaccine is composed of the H56 fusion protein, which combines three Mycobacterium tuberculosis antigens: Ag85B and ESAT-6 (associated with active infection) and Rv2660c (a latency-associated protein). This antigen component is formulated with the IC31 adjuvant system, which consists of a cationic antimicrobial peptide (KLK) and a synthetic toll-like receptor 9 (TLR9) agonist oligonucleotide (ODN1a). The vaccine is designed to elicit a robust Th1-type cell-mediated immune response to protect against initial TB infection, prevent the reactivation of latent TB, and potentially serve as a therapeutic adjunct. It has been evaluated in Phase I and Phase IIa clinical trials for safety and immunogenicity in HIV-negative adults.
- Brand names
- AERAS-456AERAS456AERAS 456
- Other names
- H56:IC31H56/IC31
02
Targets
Ag85B (Antigen 85B)ESAT-6 (Early secretory antigenic target 6)Rv2660c (Mycobacterium tuberculosis Rv2660c)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on H56 + IC31.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H56 + IC31.